Pharmaceutical Executive
Schizophrenia experts interpret the result of an extensive head-to-head comparison of five treatments. Schizophrenia patients frequently change or discontinue treatments. The jury is out on some side effects.
Pharmaceutical Executive-09-27-2005
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
